Atara Biotherapeutics, Inc. (ATRA) Stock Analysis & Investment Frameworks
Atara Biotherapeutics, Inc. (ATRA) stock analysis on Invetso. Review Atara Biotherapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Atara Biotherapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Atara Biotherapeutics, Inc. Key Financial Metrics
- Market Cap: $93.85M
- Revenue: $120.77M
- P/E Ratio: 2.87
- ROE: 44.67%
- ROIC: -93.14%
- Dividend Yield: N/A
About Atara Biotherapeutics, Inc.
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Atara Biotherapeutics, Inc. Investment Frameworks
Invetso analyzes Atara Biotherapeutics, Inc. (ATRA) across the following frameworks:
- Atara Biotherapeutics, Inc. 10Y Growth Potential
- Atara Biotherapeutics, Inc. Scenario Analysis
- Atara Biotherapeutics, Inc. Risks & Opportunities
- Atara Biotherapeutics, Inc. Economic Moat
- Atara Biotherapeutics, Inc. Business Model
- Atara Biotherapeutics, Inc. Management
- Atara Biotherapeutics, Inc. SWOT Analysis
- Atara Biotherapeutics, Inc. Porter's 5 Forces
- Atara Biotherapeutics, Inc. PESTLE Analysis
- Atara Biotherapeutics, Inc. ESG Analysis